EverMed Inc.

Founded in 2024 and based in Tokyo, Japan, EverMed Inc. operates as a company that creates exosome-based therapies for respiratory diseases, targeting conditions like IPF and COPD through cell-based methods to enhance lung health and function. The company is led by its founder, Yu Fujita. In August 2024, EverMed Inc.

raised JPY 250 million in venture funding from WASEDA University Ventures. The company’s primary product, EM-001, targets IPF, a progressive and often fatal lung disease affecting over a million patients globally. EM-001 addresses upstream disease mechanisms, including cellular senescence. EM-001 is designed to inhibit lung cell aging, inflammation, and fibrosis, aiming to halt IPF progression derived from bronchial epithelial cell exosomes.

Additionally, EVerMed is developing EM-002 for COPD, a chronic condition impacting 200 million people worldwide. EM-002 regenerates normal lung cells and restores respiratory function that utilizes exosomes from pulmonary fibroblasts, promoting the repair and differentiation of alveolar epithelial precursor cells. The organization plans to use the August 2024 investment to support its development of novel EV-based therapies targeting root causes of challenging respiratory diseases like IPF and COPD.